Neurochemical Research

, Volume 32, Issue 8, pp 1357–1364 | Cite as

Modulation of [3H]Dopamine Release by Glutathione in Mouse Striatal Slices

  • Réka Janáky
  • Róbert Dohovics
  • Pirjo Saransaari
  • Simo S. Oja
Original Paper


Glutathione (γ-glutamylcysteinylglycine, GSH and oxidized glutathione, GSSG), may function as a neuromodulator at the glutamate receptors and as a neurotransmitter at its own receptors. We studied now the effects of GSH, GSSG, glutathione derivatives and thiol redox agents on the spontaneous, K+- and glutamate-agonist-evoked releases of [3H]dopamine from mouse striatal slices. The release evoked by 25 mM K+ was inhibited by GSH, S-ethyl-, -propyl-, -butyl- and pentylglutathione and glutathione sulfonate. 5,5′-Dithio-bis-2-nitrobenzoate (DTNB) and l-cystine were also inhibitory, while dithiothreitol (DTT) and l-cysteine enhanced the K+-evoked release. Ten min preperfusion with 50 μM ZnCl2 enhanced the basal unstimulated release but prevented the activation of K+-evoked release by DTT.

Kainate and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) evoked dopamine release but the other glutamate receptor agonists N-methyl-d-aspartate (NMDA), glycine (1 mM) and trans-1-aminocyclopentane-1,3-dicarboxylate (t-ACPD, 0.5 mM), and the modulators GSH, GSSG, glutathione sulfonate, S-alkyl-derivatives of glutathione, DTNB, cystine, cysteine and DTT (all 1 mM) were without effect. The release evoked by 1 mM glutamate was enhanced by 1 mM GSH, while GSSG, glutathionesulfonate and S-alkyl derivatives of glutathione were generally without effect or inhibitory. NMDA (1 mM) evoked release only in the presence of 1 mM GSH but not with GSSG, other peptides or thiol modulators. l-Cysteine (1 mM) enhanced the glutamate-evoked release similarly to GSH. The activation by 1 mM kainate was inhibited by S-ethyl-, -propyl-, and -butylglutathione and the activation by 0.5 mM AMPA was inhibited by S-ethylglutathione but enhanced by GSSG.

Glutathione alone does not directly evoke dopamine release but may inhibit the depolarization-evoked release by preventing the toxic effects of high glutamate, and by modulating the cysteine–cystine redox state in Ca2+ channels. GSH also seems to enhance the glutamate-agonist-evoked release via both non-NMDA and NMDA receptors. In this action, the γ-glutamyl and cysteinyl moieties of glutathione are involved.


Dopamine release Striatal slices Glutathione Glutathione derivatives 



The skilful technical assistance of Ms Oili Pääkkönen, Ms. Irma Rantamaa and Ms Sari Luokkala is gratefully acknowledged. The study was financially supported by the competitive research funding of Pirkanmaa Hospital District.


  1. 1.
    Lenhoff HM (1998) The discovery of the GSH receptor in hydra and its evolutionary significance. In: Shaw CA (ed) Glutathione in the nervous system. Taylor & Francis, Washington, DC, pp 25–43Google Scholar
  2. 2.
    Shaw CA (1998) Multiple roles of glutathione in the nervous system. In: Shaw CA (ed) Glutathione in the nervous system. Taylor & Francis, Washington, DC, pp 3–23Google Scholar
  3. 3.
    Janáky R, Shaw CA, Varga V, Hermann A, Dohovics R, Saransaari P, Oja SS (2000) Specific glutathione binding sites in pig cerebral cortical synaptic membranes. Neuroscience 95:617–624PubMedCrossRefGoogle Scholar
  4. 4.
    Shaw CA, Pasqualotto BA, Curry K (1996) Glutathione-induced sodium currents in neocortex. Neuroreport 7:1149–1152PubMedCrossRefGoogle Scholar
  5. 5.
    Zängerle L, Cuénod M, Winterhalter KH, Do KQ (1992) Screening of thiol compounds: depolarization-induced release of glutathione and cysteine from rat brain slices. J Neurochem 59:181–189PubMedCrossRefGoogle Scholar
  6. 6.
    Ogita K, Kitago T, Nakamuta H, Fukuda Y, Koida M, Ogawa Y, Yoneda Y (1986) Glutathione-induced inhibition of Na+-independent and -dependent bindings of L-[3H]glutamate in rat brain. Life Sci 39:2411–2418PubMedCrossRefGoogle Scholar
  7. 7.
    Oja SS, Varga V, Janáky R, Kontro P, Aarnio T, Marnela K-M (1988) Glutathione and glutamatergic neurotransmission in the brain. In: Cavalheiro EA, Lehmann J, Turski L (eds) Frontiers in excitatory amino acid research. Alan R Liss, New York, pp 75–78Google Scholar
  8. 8.
    Varga V, Janáky R, Marnela K-M, Gulyás J, Kontro P, Oja SS (1989) Displacement of excitatory amino acid receptor ligands by acidic oligopeptides. Neurochem Res 14:1223–1227PubMedCrossRefGoogle Scholar
  9. 9.
    Janáky R, Varga V, Oja SS, Saransaari P (1994) Release of [3H]GABA evoked by glutamate agonists from hippocampal slices: effects of dithiothreitol and glutathione. Neurochem Int 24:575–582PubMedCrossRefGoogle Scholar
  10. 10.
    Oja SS, Janáky R, Saransaari P, Jenei Zs, Varga V (1995) Interaction of glutathione derivatives with brain 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. Proc West Pharmacol Soc 38:9–11PubMedGoogle Scholar
  11. 11.
    Janáky R, Varga V, Jenei Zs, Saransaari P, Oja SS (1998) Glutathione and glutathione derivatives: possible modulators of ionotropic glutamate receptors. In: Shaw CA (ed) Glutathione in the nervous system. Taylor & Francis, Washington, DC, pp 163–196Google Scholar
  12. 12.
    Terramani T, Kessler M, Lynch G, Baudry M (1988) Effects of thiol-reagents on [3H]α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to rat telencephalic membranes. Mol Pharmacol 34:117–123PubMedGoogle Scholar
  13. 13.
    Aizenman E., Lipton SA, Loring RH (1989) Selective modulation of NMDA responses by reduction and oxidation. Neuron 2:1257–1263PubMedCrossRefGoogle Scholar
  14. 14.
    Janáky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y, Shaw CA (1999) Glutathione and signal transduction in the mammalian CNS. J Neurochem 73:889–902PubMedCrossRefGoogle Scholar
  15. 15.
    Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33:305–310PubMedCrossRefGoogle Scholar
  16. 16.
    Bannon MJ, Goedert M, Williams B (1984) The possible relationship of glutathione, melanin, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson’s disease. Biochem Pharmacol 33:2697–2698PubMedCrossRefGoogle Scholar
  17. 17.
    Perry TL, Yong VW (1986) Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67:269–274PubMedCrossRefGoogle Scholar
  18. 18.
    Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Yudim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515–520PubMedCrossRefGoogle Scholar
  19. 19.
    Yong VW, Perry TL, Krisman AA (1986) Depletion of glutathione in brainstem of mice by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant treatment. Neurosci Lett 63:56–60PubMedCrossRefGoogle Scholar
  20. 20.
    Andersen JK, Mo JQ, Hom DG, Lee FY, Harnish P, Hamill RW, McNeill TH (1996) Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J Neurochem 67:2164–2171PubMedCrossRefGoogle Scholar
  21. 21.
    Masuoka DT, Jonsson G, Finch CE (1979) Aging and unusual catecholamine-containing structures in the mouse brain. Brain Res 169:335–341PubMedCrossRefGoogle Scholar
  22. 22.
    McNeill TH, Koek LL, Haycock JW (1984) Age-correlated changes in dopaminergic nigrostriatal perikarya of the C57BL/6Nni mouse. Mech Ageing Dev 24:293–307PubMedCrossRefGoogle Scholar
  23. 23.
    Felten DL, Felten SY, Fuller RW, Romano DT, Smalstig EB, Wong DT, Clemens JA (1992) Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged F344 rats. Neurobiol Aging 13:339–351PubMedCrossRefGoogle Scholar
  24. 24.
    Pileblad E, Magnusson T (1990) Effective depletion of glutathione in rat striatum and substantia nigra by L-buthionine sulfoximine in combination with 2-cyclohexen-1-one. Life Sci 47:2333–2342PubMedCrossRefGoogle Scholar
  25. 25.
    Paxinos G, Franklin WBJ (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic Press, San DiegoGoogle Scholar
  26. 26.
    DiChiara G, Morelli M (1993) Dopamine-acetylcholine-glutamate interactions in the striatum: a working hypothesis. Adv Neurol 60:102–106Google Scholar
  27. 27.
    Chéramy A, Desce JM, Godeheu, Glowinski J (1994) Presynaptic control of dopamine synthesis and release by excitatory amino acids in rat striatal synaptosomes. Neurochem Int 25:145–154PubMedCrossRefGoogle Scholar
  28. 28.
    Morari M, O’Connor WT, Darvelid M, Ungerstedt U, Bianchi C, Fuxe K (1996) Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat. I. Effects of perfusion with tetrodotoxin and low-calcium medium. Neuroscience 72:79–87PubMedCrossRefGoogle Scholar
  29. 29.
    Janáky R, Varga V, Hermann A, Saransaari P, Oja SS (2000) Mechanisms of L-cysteine neurotoxicity. Neurochem Res 25:1397–1405PubMedCrossRefGoogle Scholar
  30. 30.
    Cho Y, Bannai S (1990) Uptake of glutamate and cystine in C-6 glioma cells and in cultured astrocytes. J Neurochem 55:2091–2097PubMedCrossRefGoogle Scholar
  31. 31.
    Gilbert KR, Aizenman E, Reynolds IJ (1991) Oxidized glutathione modulates N-methyl-D-aspartate- and depolarization-induced increases in intracellular Ca2+ in cultured rat forebrain neurons. Neurosci Lett 133:11–14CrossRefGoogle Scholar
  32. 32.
    Ruppersberg JP, Stocker M, Pongs O, Heinemann SH, Frank K, Koenen M (1991) Regulation of fast inactivation of cloned mammalian Ik(A) channels by cysteine oxidation. Nature 352:711–714PubMedCrossRefGoogle Scholar
  33. 33.
    Maret W (1998) The glutathione redox state and zinc mobilization from metallothionein and other proteins with zinc-sulfur coordination sites. In: Shaw CA (ed) Glutathione in the nervous system. Taylor & Francis, Washington, DC, pp 257–273Google Scholar
  34. 34.
    Hermann A, Varga V, Janáky R, Dohovics R, Saransaari P, Oja SS (2000) Interference of S-nitrosoglutathione with the binding of ligands to ionotropic glutamate receptors in pig cerebral cortical synaptic membranes. Neurochem Res 25:1119–1124PubMedCrossRefGoogle Scholar
  35. 35.
    Chinta SJ, Andersen JK (2006) Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson’s disease. Free Rad Biol Med 41:1442–1448PubMedCrossRefGoogle Scholar
  36. 36.
    Hsu M, Srinivas B, Kumar J, Subramanian R, Andersen J (2005) Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells via an NO-mediated mitochondrial pathway not involving peroxynitrite: implications for Parkinson’s disease. J Neurochem 92:1091–1103PubMedCrossRefGoogle Scholar
  37. 37.
    Li Y-J, Scott WK, Zhang L, Lin P-I, Oliveira SA, Skelly T, Doraiswamy MP, Welsh-Bohmer KA, Martin ER, Haines JL, Pericak-Vance MA, Vance JM (2006) Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases. Neurobiol Aging 27:1087–1093PubMedCrossRefGoogle Scholar
  38. 38.
    Duncan MW, Marini AM, Watters R, Kopin IJ, Markey SP (1992) Zinc, a neurotoxin to cultured neurons, contaminates Cycad flour prepared by traditional Guamanian methods. J Neurosci 12:1523–1537PubMedGoogle Scholar
  39. 39.
    Leviel V, Gobert A, Guibert B (1990) The glutamate-mediated release of dopamine in the rat striatum: further characterization of the dual excitatory-inhibitory function. Neuroscience 39:305–312PubMedCrossRefGoogle Scholar
  40. 40.
    Krebs MO, Desce JM, Kemel ML, Gauchy C, Godehey G, Chéramy A, Glowinski J (1991) Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J Neurochem 56:81–85PubMedCrossRefGoogle Scholar
  41. 41.
    O’Connor WT, Drew KL, Ungerstedt U (1995) Differential cholinergic regulation of dopamine release in the dorsal and ventral neostriatum of the rat: an in vivo microdialysis study. J Neurosci 15:8353–8361PubMedGoogle Scholar
  42. 42.
    Varga V, Jenei Zs, Janáky R, Saransaari P, Oja SS (1997) Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. Neurochem Res 22:1165–1171PubMedCrossRefGoogle Scholar
  43. 43.
    Sucher NJ, Lipton SA (1991) Redox modulatory site of the NMDA receptor-channel complex: regulation by oxidized glutathione. J Neurosci Res 30: 582–591PubMedCrossRefGoogle Scholar
  44. 44.
    Ogita K, Enomoto R, Nakahara F, Ishitsubo N, Yoneda Y (1995) A possible role of glutathione as an endogenous agonist in the N-methyl-D-asparate recognition domain in rat brain. J Neurochem 64:1088–1096PubMedCrossRefGoogle Scholar
  45. 45.
    Clow DW, Jhamandas K (1989) Characterization of L-glutamate action on the release of endogenous dopamine from the rat caudate-putamen. J Pharmacol Exp Ther 248:722–728PubMedGoogle Scholar
  46. 46.
    Borkowska HD, Oja SS, Saransaari P, Albrecht J (1997) Release of [3H]dopamine from striatal and cerebral cortical slices from rats with thioacetamide-induced hepatic encephalopathy: different responses to stimulation by potassium ion and agonists of ionotrophic glutamate receptors. Neurochem Res 22:101–106PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Réka Janáky
    • 1
  • Róbert Dohovics
    • 1
  • Pirjo Saransaari
    • 1
  • Simo S. Oja
    • 2
  1. 1.Brain Research CenterUniversity of Tampere Medical SchoolTampereFinland
  2. 2.The Centre for Laboratory MedicineTampere University HospitalTampereFinland

Personalised recommendations